Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
A SABCS 2019 session encouraged oncologists to scrutinize whether presentations are practice changing, and included a look at controversial data from KEYNOTE-522.
A nationwide outbreak of EVALI reports has highlighted the unknowns about one of the most popular forms of inhalation drug use in the US.
The cancer field is not immune to the challenges of out-of-network and surprise billing.
Combining PD-1 blockade with PAK4 inhibitors could boost the number of patients helped by the therapy.